Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis

NCT07387549 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT07387549
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07387549 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis
Lead sponsor
Ipsen
Phase
Phase 3
Overall status
Recruiting
Start date
May 14, 2026
Completion date
May 31, 2031
Enrollment
350 (estimated)
Sites
231

Conditions

As the registry lists them; a condition with its own page is linked.

primary sclerosing cholangitis